Ramsay's Trap Resets With COVID Brain Fog

A team of researchers recently found that cognitive impairment from at least one COVID variant can reverse itself — but the qualifier matters more than the discovery.

"At least for one variant" is not an abundance of caution. It is the shape of a familiar trap resetting. In 1988, a British virologist named Melvin Ramsay published findings on myalgic encephalomyelitis patients who had recovered after acute infection, documenting symptom improvement that seemed to validate a simple narrative. The disease was not permanent.

The problem was that Ramsay had studied the acute phase — people months past infection. His work became the foundation for a claim that generalized outward to everyone who stayed sick. Decades of ME/CFS patients, still immobilized years or decades later, were told they matched his cohort and should recover.

The fact that they didn't was repositioned as a psychiatric failure rather than a biological one. The reversibility Ramsay had documented in one temporal window became evidence that permanent disability was impossible. The COVID cognitive impairment research now replicates that exact architecture, with short-term improvements in one variant being reported in ways that collapse the distinction between acute recovery and chronic disease. A person experiencing brain fog in month two is not the same as someone still fogged in month twenty-four. The mechanisms may differ, the prognosis certainly does. Yet the qualifier is being weaponized as optimism rather than interrogated as a boundary.

What changes this time depends on whether the field has learned to separate temporal windows from universal claims. The mail carrier who develops cognitive symptoms and recovers in weeks has had a different experience than the one whose career has fragmented across two years of impairment. Claiming hope without naming timeline, without distinguishing acute from chronic, without specifying which patients are actually recovering, imports yesterday's credibility crisis into today's research. The reversibility that matters is not whether symptoms can improve in principle. It is whether they improve for the person whose life is being lived in the meantime.